Compare

Galectin Therapeutics Inc vs Marker Therapeutics, Inc. vs Genelux Corp vs Evofem Biosciences, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearGalectin Therapeutics Inc
GALT
Marker Therapeutics, Inc.
MRKR
Genelux Corp
GNLX
Evofem Biosciences, Inc.
EVFM
Year ended2025-12-312025-12-312025-12-312025-12-31
Revenuen/a$3.55M$8.0K$20.18M
Revenue growth (YoY)n/a-46.2%0.0%+4.2%
Gross marginn/an/an/a77.1% (computed)
Operating marginn/a-363.5%n/m16.7%
Net marginn/a-343.0%n/m1.9%
Net income-$30.84M-$12.16M-$32.15M$391.0K
EPS (Diluted)-$0.48-$0.79-$0.86$0.00
Operating cash flow-$23.88M-$12.01M-$25.27M-$1.99M
Free cash flown/an/a-$26.37M-$2.00M
Cash & equivalents$17.72M$16.07M$5.33M$578.0K
Total assets$19.53M$19.07M$19.03M$20.27M
Total liabilities$145.73M$2.27M$7.48M$89.71M
Shareholders' equity-$127.92M$16.80M$11.54M-$74.34M
Return on year-end equityn/a-72.4%-278.5%n/a
Shares outstanding65.20M16.70M38.14M126.69M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearGalectin Therapeutics IncMarker Therapeutics, Inc.Genelux CorpEvofem Biosciences, Inc.
Latestn/a$3.55M
Ended 2025-12-31
$8.0K
Ended 2025-12-31
$20.18M
Ended 2025-12-31
1 year earliern/a$6.59M
Ended 2024-12-31
$8.0K
Ended 2024-12-31
$19.36M
Ended 2024-12-31
2 years earliern/a$3.31M
Ended 2023-12-31
$170.0K
Ended 2023-12-31
$18.22M
Ended 2023-12-31
3 years earliern/a$3.51M
Ended 2022-12-31
$11.07M
Ended 2022-12-31
$16.84M
Ended 2022-12-31
4 years earliern/a$1.24M
Ended 2021-12-31
n/a$8.24M
Ended 2021-12-31